{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976452",
  "id": "02976452",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250804",
  "time": "0934",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250804/pdf/06mhk1f91vq65q.pdf",
  "summary": "**Capital Raising Announcement Summary:**  \n\n- **Structure**: Placement (two tranches) with free-attaching options.  \n- **Total Capital**:  \n  - **Ordinary Shares (IBX)**: 188,333,333 shares at **AUD 0.015/share** (Tranche 2; subject to shareholder approval).  \n  - **Attaching Options (IBXO)**: 233,333,333 options (expiring 13-Dec-2027; exercise price not stated).  \n  - **Lead Manager Options**: 26,250,000 unlisted options (expiring 17-Sep-2028; exercise price **AUD 0.04**).  \n- **Key Dates**:  \n  - **Shareholder meeting for approval**: 18-Aug-2025.  \n  - **Proposed issue date**: 22-Sep-2025.  \n Seq2Seq2\n- **Use of Proceeds**: Fund Phase 1 trials for MagSense\u00ae (HER2 breast, prostate, ovarian cancer).  \n- **Fees**:  \n  - Lead Manager (CPS Capital): 2% management fee + 4% capital raising fee (payable in cash or shares).  \n  - Additional 26.25M options issued to CPS.  \n\n*Notes*: Tranche 1 (45M shares) under Listing Rule 7.1/7.1A; Tranche 2 requires approval. No underwriting.",
  "usage": {
    "prompt_tokens": 2586,
    "completion_tokens": 305,
    "total_tokens": 2891,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-04T00:01:56.673951"
}